Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient. (February 2017)

• Record Type: Journal Article
• Authors: Andrey, Diego O.; Kaiser, Laurent; Emonet, Stéphane; Erard, Veronique; Chalandon, Yves; van Delden, Christian
• Is Part Of: International journal of infectious diseases. Volume 55(2017:Feb.)
• Page Start: 24
• Page End: 26
• Publication Date: 2017-02
• Subjects: Posaconazole delayed-release tablets -- Rhizomucor pusillus -- Zygomycosis -- Mucormycosis; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2016.12.014
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Mucormycosis (zygomycosis) is an emerging fungal disease in allogeneic hematopoietic stem cell transplant recipients. Higher posaconazole plasma concentration might be obtained with posaconazole delayed-release tablets. Summary: Mucormycosis (zygomycosis) is an emerging fungal disease in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. A 30-year-old woman diagnosed with acute myelomonocytic leukemia and needing allo-HSCT presented pulmonary and cerebral infection due to Rhizomucor pusillus. This fungal infection was treated with surgical treatment and posaconazole delayed-release tablets. This strategy allowed reaching high drug levels that could not be obtained with the posaconazole solution.